Ti Zhang1, Philippe Merle2, Huaqi Wang3, Haitao Zhao4, Masatoshi Kudo5. 1. Department of Hepatic Surgery, Fudan University Shanghai Cancer Center, Shanghai Medical College, Fudan University, Shanghai, China. 2. Department of Hepatology, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, Université Lyon 1, 103 Grande rue de la Croix Rousse, Lyon, France. 3. Department of Hepatobiliary Surgery, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China. 4. Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College (CAMS & PUMC), Beijing, China. 5. Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka-Sayama, Japan.
Abstract
IMPORTANCE: Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma (HCC), and consistently it is the hotspot in clinical studies. OBJECTIVE: To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies. EVIDENCE REVIEW: We searched PubMed, MEDLINE, Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC. FINDINGS: Several clinical issues are worth reconsidering, such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems, the translation of surrogate endpoint objective response rate (ORR) benefits into overall survival (OS) benefits, and whether conversion surgery contributes to initial expectations of long-term survival or not. New concepts in novel immunotherapy and targeted therapy in combination with loco-regional therapies may improve overall survival for HCC. CONCLUSIONS AND RELEVANCE FOR REVIEWS: Comprehensive understanding of the mechanism of immunotherapy and targeted therapy contributes to better prognosis of advanced HCC and more explorative combination therapies are needed. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
IMPORTANCE: Combination therapies of anti-PD-1 and anti-angiogenesis regimens are emerging rapidly and exhibit more promising anti-tumor efficacy for advanced hepatocellular carcinoma (HCC), and consistently it is the hotspot in clinical studies. OBJECTIVE: To elaborate several issues which are warranted further consideration as more regimens are being investigated in combination therapies. EVIDENCE REVIEW: We searched PubMed, MEDLINE, Cochrane Library and Google Scholar by 2021 February for publications on combination therapies for HCC. FINDINGS: Several clinical issues are worth reconsidering, such as the evaluation on appropriate primary endpoints in phase III clinical trials as for different practical problems, the translation of surrogate endpoint objective response rate (ORR) benefits into overall survival (OS) benefits, and whether conversion surgery contributes to initial expectations of long-term survival or not. New concepts in novel immunotherapy and targeted therapy in combination with loco-regional therapies may improve overall survival for HCC. CONCLUSIONS AND RELEVANCE FOR REVIEWS: Comprehensive understanding of the mechanism of immunotherapy and targeted therapy contributes to better prognosis of advanced HCC and more explorative combination therapies are needed. 2021 Hepatobiliary Surgery and Nutrition. All rights reserved.
Authors: Andrew X Zhu; Richard S Finn; Julien Edeline; Stephane Cattan; Sadahisa Ogasawara; Daniel Palmer; Chris Verslype; Vittorina Zagonel; Laetitia Fartoux; Arndt Vogel; Debashis Sarker; Gontran Verset; Stephen L Chan; Jennifer Knox; Bruno Daniele; Andrea L Webber; Scot W Ebbinghaus; Junshui Ma; Abby B Siegel; Ann-Lii Cheng; Masatoshi Kudo Journal: Lancet Oncol Date: 2018-06-03 Impact factor: 41.316
Authors: Charlotte E Costentin; Cristina R Ferrone; Ronald S Arellano; Suvranu Ganguli; Theodore S Hong; Andrew X Zhu Journal: Liver Cancer Date: 2017-10-19 Impact factor: 11.740
Authors: Josep M Llovet; Augusto Villanueva; Jorge A Marrero; Myron Schwartz; Tim Meyer; Peter R Galle; Riccardo Lencioni; Tim F Greten; Masatoshi Kudo; Sumithra J Mandrekar; Andrew X Zhu; Richard S Finn; Lewis R Roberts Journal: Hepatology Date: 2020-09-09 Impact factor: 17.425
Authors: Alessandro Rizzo; Angela Dalia Ricci; Alessandro Di Federico; Giorgio Frega; Andrea Palloni; Simona Tavolari; Giovanni Brandi Journal: Front Oncol Date: 2021-12-17 Impact factor: 6.244